Eyenovia, Inc. (EYEN): Price and Financial Metrics
GET POWR RATINGS... FREE!
EYEN POWR Grades
- Sentiment is the dimension where EYEN ranks best; there it ranks ahead of 91.18% of US stocks.
- The strongest trend for EYEN is in Momentum, which has been heading up over the past 179 days.
- EYEN's current lowest rank is in the Quality metric (where it is better than 5.41% of US stocks).
EYEN Stock Summary
- EYEN has a market capitalization of $66,809,026 -- more than approximately only 16.02% of US stocks.
- As for revenue growth, note that EYEN's revenue has grown 66.67% over the past 12 months; that beats the revenue growth of 87.14% of US companies in our set.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for EYEN comes in at -45.76% -- higher than that of only 11.69% of stocks in our set.
- Stocks that are quantitatively similar to EYEN, based on their financial statements, market capitalization, and price volatility, are PSNL, DYAI, POWI, VLDR, and VYNE.
- EYEN's SEC filings can be seen here. And to visit EYENOVIA INC's official web site, go to www.eyenoviabio.com.
EYEN Valuation Summary
- EYEN's price/sales ratio is 6.7; this is 235% higher than that of the median Healthcare stock.
- EYEN's EV/EBIT ratio has moved up 24.2 over the prior 59 months.
Below are key valuation metrics over time for EYEN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| EYEN | 2022-11-25 | 6.7 | 3.3 | -3.5 | -2.7 |
| EYEN | 2022-11-23 | 6.8 | 3.4 | -3.6 | -2.8 |
| EYEN | 2022-11-22 | 6.5 | 3.2 | -3.4 | -2.6 |
| EYEN | 2022-11-21 | 6.5 | 3.2 | -3.4 | -2.6 |
| EYEN | 2022-11-18 | 6.4 | 3.1 | -3.4 | -2.5 |
| EYEN | 2022-11-17 | 6.4 | 3.1 | -3.4 | -2.5 |
EYEN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- EYEN has a Quality Grade of D, ranking ahead of 6.86% of graded US stocks.
- EYEN's asset turnover comes in at 0.201 -- ranking 199th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows EYEN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.201 | 0.6 | 2.595 |
| 2021-03-31 | 0.160 | 0.6 | 2.859 |
| 2020-12-31 | 0.093 | 0.6 | 4.639 |
| 2020-09-30 | 0.000 | NA | 11.497 |
| 2020-06-30 | 0.000 | NA | 13.846 |
| 2020-03-31 | 0.000 | NA | 12.392 |
EYEN Price Target
For more insight on analysts targets of EYEN, see our EYEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $15.50 | Average Broker Recommendation | 1.33 (Strong Buy) |
EYEN Stock Price Chart Interactive Chart >
EYEN Price/Volume Stats
| Current price | $1.97 | 52-week high | $4.21 |
| Prev. close | $1.97 | 52-week low | $1.52 |
| Day low | $1.93 | Volume | 96,241 |
| Day high | $2.02 | Avg. volume | 179,518 |
| 50-day MA | $2.08 | Dividend yield | N/A |
| 200-day MA | $2.20 | Market Cap | 67.40M |
Eyenovia, Inc. (EYEN) Company Bio
Eyenovia, Inc., a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst that has completed Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat that has completed Phase II clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.
Latest EYEN News From Around the Web
Below are the latest news stories about EYENOVIA INC that investors may wish to consider to help them evaluate EYEN as an investment opportunity.
Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt FundTransaction proceeds, together with cash on-hand, expected to fund operations through late 2023/early 2024, including potential FDA approval of MydCombi™NEW YORK, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, |
Eyenovia to Present at Upcoming BTIG Ophthalmology DayNEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced management will present at the BTIG Ophthalmology Day taking place virtually on November 29, 2022. Presentation details are below: BTIG |
Eyenovia Third Quarter 2022 Earnings: US$0.21 loss per share (vs US$0.21 loss in 3Q 2021)Eyenovia ( NASDAQ:EYEN ) Third Quarter 2022 Results Key Financial Results Net loss: US$7.31m (loss widened by 31% from... |
Eyenovia Reports Third Quarter 2022 Financial Results and Provides Business UpdateAnnounced positive results from the second Phase 3 study of MicroLine in presbyopia, VISION-2; Company planning to meet with the FDA to gain alignment on regulatory path forward as a drug/device combination product Company to host conference call and webcast today, November 10, at 4:30 pm ET NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug |
Eyenovia to Report Third Quarter 2022 Results on Thursday, November 10Company to host an investor conference call and webcast at 4:30pm ET on that dayNEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs as well as out-licensing for additional indications, today announced that the Company will release financial results for the third quarter ended September 30, 2022 on Thursday, Novembe |
EYEN Price Returns
| 1-mo | -8.80% |
| 3-mo | -3.43% |
| 6-mo | -12.05% |
| 1-year | -46.03% |
| 3-year | -54.08% |
| 5-year | N/A |
| YTD | -50.75% |
| 2021 | -33.99% |
| 2020 | 35.27% |
| 2019 | 57.19% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...